Genomic profile of urothelial carcinoma of the upper tract from ureteroscopic biopsy: Feasibility and validation using matched radical nephroureterectomy specimens Journal Article


Authors: Bagrodia, A.; Audenet, F.; Pietzak, E. J.; Kim, K.; Murray, K. S.; Cha, E. K.; Sfakianos, J. P.; Iyer, G.; Singla, N.; Arcila, M.; Bochner, B. H.; Al-Ahmadie, H. A.; Solit, D. B.; Coleman, J. A.
Article Title: Genomic profile of urothelial carcinoma of the upper tract from ureteroscopic biopsy: Feasibility and validation using matched radical nephroureterectomy specimens
Abstract: Urothelial carcinoma of the upper tract (UTUC) presents specific challenges regarding accurate staging and tumor sampling. We aimed to assess the feasibility of applying next-generation sequencing to biopsy specimens and gauged the concordance of their genetic profiles with matched radical nephroureterectomy (RNU) specimens. Of the 39 biopsy specimens collected, 36 (92%) had adequate material for sequencing using a hybridization-based exon capture assay (MSK-IMPACT). The most frequently altered genes across the patient cohort were consistent with the urothelial carcinoma-associated alterations identified in a cohort of 130 RNU specimens previously sequenced at our center, including mutations in the TERT promoter (64%), hotspot activating mutations in FGFR3 (64%), and frequent mutations in chromatin remodeling genes. For 12 patients, a matching tumor sample from a subsequent RNU was sequenced. We found a high level of concordance between matched biopsy and RNU specimens, up to 92% for the likely pathogenic alterations. Patient summary: We evaluated the feasibility of genomic characterization of tumor tissue collected at the time of ureteroscopic biopsy and found high concordance with subsequent radical nephroureterectomy specimens. Molecular characterization of urothelial carcinoma of the upper tract biopsies could guide treatment decision-making and identify high-risk patients who could benefit from neoadjuvant chemotherapy and low-risk patients who could benefit from conservative or organ-sparing strategies. © 2018 European Association of Urology
Keywords: biomarkers; prediction; genomics; upper tract urothelial carcinoma; transitional cell carcinoma
Journal Title: European Urology Focus
Volume: 5
Issue: 3
ISSN: 2405-4569
Publisher: Elsevier B.V.  
Date Published: 2019-05-01
Start Page: 365
End Page: 368
Language: English
DOI: 10.1016/j.euf.2018.01.005
PROVIDER: scopus
PUBMED: 29396293
PMCID: PMC7583604
DOI/URL:
Notes: Article -- Export Date: 2 August 2019 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jonathan Coleman
    341 Coleman
  2. David Solit
    779 Solit
  3. Gopakumar Vasudeva Iyer
    342 Iyer
  4. Bernard Bochner
    468 Bochner
  5. Maria Eugenia Arcila
    657 Arcila
  6. Eugene K. Cha
    99 Cha
  7. Katie S Murray
    16 Murray
  8. Kwanghee   Kim
    43 Kim
  9. Eugene J Pietzak
    116 Pietzak
  10. Francois Jean Marie Audenet
    16 Audenet